In women with osteoporosis, new or worsening severe vertebral fractures occurred less often with teriparatide than placebo.
In plain wordsIn women with osteoporosis, teriparatide reduced new or worsening severe vertebral fractures compared with placebo.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- DecreaseNew or worsening severe vertebral fracture
- Study
n = 892
- Comparator
- Placebo
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 20 mug/day · Median 19 monthsAs given in this study (human).
Measurements
- Fracture incidence
- 0.7%
- teriparatide
- Fracture incidence
- 4.7%
- placebo
- Relative risk reduction
- 86%
- teriparatide versus placebo
Source sentences
After a median of 19 months of therapy, new or worsening SQ3 vertebral fractures occurred in 21 of 448 patients (4.7%) in the placebo group compared with 3 of 444 patients (0.7%) in the 20 mug/day teriparatide group.
The risk of developing a new or worsened SQ3 vertebral fracture was reduced by 86% (P < 0.001) in patients treated with 20 mug/day teriparatide.
1 context sentence(design, population, supporting numbers)
We sought to determine whether vertebral fracture severity was associated with HRQOL scores, and if so, to determine the effects of teriparatide (recombinant human parathyroid hormone 1-34) on vertebral fracture grades that most strongly impact HRQOL in postmenopausal women with osteoporosis.